Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A

3(37.5%)

Phase 2

3(37.5%)

Phase 3

1(12.5%)

Phase 1

1(12.5%)

8Total

N/A(3)

Phase 2(3)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05905003Active Not Recruiting

AMP SCZ® Observational Study: PREDICT-DPACC

Role: collaborator

NCT02751632Phase 3Completed

The Staged Treatment in Early Psychosis Study

Role: lead

NCT07114887Not ApplicableNot Yet Recruiting

Virtual Reality for Vocational Recovery

Role: lead

NCT05957848Phase 2Recruiting

Guanfacine Extended-release for Adolescents With Cannabis Use

Role: lead

NCT06463470Not ApplicableRecruiting

Cognitive Behavioural Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR)

Role: lead

NCT06894836Phase 2Not Yet Recruiting

Hybrid Type 2 Implementation-Effectiveness Trial of a Third Wave Virtual Reality Treatment for Youth Depression/Anxiety

Role: lead

NCT06364332Not ApplicableRecruiting

Chatsafe Netherlands: Improving Safe Suicide Communication for Young People on Social Media

Role: collaborator

NCT02070211Phase 2Unknown

Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome.

Role: collaborator

NCT01399502Phase 1Completed

Promotion of Self-help Strategies for Depression

Role: lead

All 9 trials loaded